-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $612

Benzinga·04/10/2026 16:12:13
Listen to the news
Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $596 to $612.